RxDoctor Payments Data

Alex Campbell, MD

Cardiovascular Disease · Minneapolis, MNNPI 1902041296

Payments from drug & device makers

$2,557in general payments, 2019–2025

Across 40 payments — averaging $63.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$716
  • Abbott$589
  • Medtronic$418
  • Edwards Lifesciences$196
  • GE HealthCare$142
  • Irhythm Technologies, Inc.$96
  • plus $399 from 7 others

What the payments were for

  • Travel & lodging$36914%
  • Food & beverage$2,18886%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,557 in reported general payments places this provider in the 50th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$101,443
Medicare patients
822
Services billed
1,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$249,244
EntrestoSacubitril/Valsartan83$70,489
XareltoRivaroxaban49$65,803
FarxigaDapagliflozin Propanediol20$21,532
Repatha SureclickEvolocumab16$14,121
Rosuvastatin Calcium256$3,949
Metoprolol Succinate156$3,809
Atorvastatin Calcium156$2,048
AliskirenAliskiren Hemifumarate12$1,712
Carvedilol129$1,700
Lisinopril95$1,379
Eplerenone16$1,288
Furosemide148$1,234
Spironolactone103$1,039
Flecainide Acetate34$1,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$249,244231 claims
Johnson & JohnsonXarelto$39$65,80349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →